Samsara BioCapital LLC Takes Position in Septerna, Inc. (NASDAQ:SEPN)

Samsara BioCapital LLC acquired a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,768,520 shares of the company's stock, valued at approximately $63,399,000. Septerna makes up about 8.6% of Samsara BioCapital LLC's holdings, making the stock its 3rd largest holding. Samsara BioCapital LLC owned about 6.24% of Septerna as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Tower Research Capital LLC TRC purchased a new stake in shares of Septerna in the 4th quarter valued at $25,000. New York State Common Retirement Fund acquired a new stake in shares of Septerna in the 4th quarter worth $32,000. Legal & General Group Plc purchased a new stake in shares of Septerna during the 4th quarter valued at approximately $42,000. Summit Investment Advisors Inc. purchased a new position in Septerna during the fourth quarter worth about $45,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of Septerna in the 4th quarter valued at $61,000.

Septerna Stock Performance

NASDAQ:SEPN traded down $0.22 during mid-day trading on Monday, reaching $7.26. The stock had a trading volume of 37,370 shares, compared to its average volume of 417,528. Septerna, Inc. has a 1-year low of $4.17 and a 1-year high of $28.99. The business has a 50 day simple moving average of $6.10.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. The business had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.13 million. On average, equities research analysts forecast that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Wells Fargo & Company decreased their price target on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating for the company in a research note on Friday, March 28th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $50.00 price objective on shares of Septerna in a report on Tuesday, February 11th.

Insider Buying and Selling

In other news, CFO Gil M. Labrucherie bought 10,500 shares of the business's stock in a transaction on Wednesday, February 19th. The shares were bought at an average cost of $5.51 per share, with a total value of $57,855.00. Following the purchase, the chief financial officer now directly owns 10,500 shares in the company, valued at $57,855. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Alan Ezekowitz purchased 41,355 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average cost of $6.00 per share, for a total transaction of $248,130.00. Following the completion of the transaction, the director now directly owns 104,101 shares of the company's stock, valued at $624,606. This trade represents a 65.91 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 74,346 shares of company stock worth $439,670 in the last three months.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.